News

There is widespread hope for curbing HIV after the United States Food and Drug Administration (FDA) approved an injectable ...
Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...
The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...
Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...
The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...
The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...
Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...